The Precision Play: Atavistik Bio's $160M Bet on Allosteric Drugs

CAMBRIDGE, Mass. – March 05, 2026 – In a significant show of investor confidence, clinical-stage biotechnology company Atavistik Bio announced it has closed a $40 million extension to its Series B financing, bringing the total proceeds for the round to an impressive $160 million. The new capital comes from RA Capital Management, a prominent life sciences investor, joining an already robust syndicate that includes Nextech Invest, The Column Group, Lux Capital, and Regeneron Ventures.

The substantial funding is earmarked to propel two of the company’s lead programs into and through critical clinical milestones. The proceeds will fuel the clinical development of ATV-1601, a potential first-in-class oral therapy for Hereditary Hemorrhagic Telangiectasia (HHT), and advance its JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms (MPNs) through clinical proof of concept.

A Major Vote of Confidence in a Competitive Market

The successful upsized financing round is a powerful endorsement of Atavistik Bio’s strategy and scientific platform, particularly in a competitive biotech funding environment. Securing $160 million in a single round from a syndicate of top-tier investors validates the company's focus on developing selective allosteric therapeutics—a sophisticated approach aimed at creating safer and more effective medicines.

“Our Series B round, backed by a highly respected syndicate, reflects strong belief in our selective allosteric programs and our focus to advance meaningful therapies for patients with severe diseases,” said Bryan Stuart, Chief Executive Officer at Atavistik Bio. “This additional funding further strengthens our ability to accelerate the development of best-in-class therapies designed to deliver superior efficacy, improved tolerability profiles, and potentially transformative outcomes for patients.”

The addition of RA Capital Management to the syndicate is particularly noteworthy. The firm is known for its deep scientific diligence and strategic investments in companies with the potential to shift treatment paradigms. Their participation underscores the perceived value and promise of Atavistik's pipeline.

“We are pleased to support Atavistik Bio in this next phase of growth as the company is at the forefront of developing transformative therapies for HHT and MPNs,” commented Nandita Shangari, PhD, Managing Director at RA Capital Management. “Atavistik Bio’s highly experienced team and a pipeline of high-quality programs targeting significant unmet need, position the company to create meaningful value.”

The Scientific Edge: Redefining Drug Targets with Allostery

At the core of Atavistik Bio's strategy is its expertise in allosteric modulation. Unlike traditional drugs that bind to a protein's active (orthosteric) site to block its function, allosteric inhibitors bind to a separate, distinct site. This seemingly subtle difference has profound implications for drug design and efficacy.

Allosteric sites are often less conserved across related protein families than active sites. This allows for the design of highly selective drugs that can distinguish between closely related protein isoforms. The result is a precision-targeted therapy that hits its intended target while sparing others, thereby minimizing the off-target effects that plague many conventional inhibitors and lead to dose-limiting toxicities.

This enhanced selectivity is central to both of Atavistik’s lead programs. By fine-tuning protein function rather than employing a brute-force blockade, allosteric modulators can offer a more nuanced therapeutic effect, preserving essential biological functions and improving a drug's overall safety profile. This makes them particularly suitable for chronic diseases where long-term tolerability is critical. The approach also opens the door to modulating proteins that have historically been considered “undruggable” due to the nature of their active sites.

A New Horizon for Hereditary Hemorrhagic Telangiectasia

Nowhere is the need for a new therapeutic approach more evident than in Hereditary Hemorrhagic Telangiectasia (HHT). This severe, inherited bleeding disorder affects more than 1.6 million people globally, yet there are currently no FDA-approved therapies. Patients suffer from abnormal blood vessel formation, leading to frequent and severe nosebleeds, chronic anemia, and life-threatening vascular malformations in organs like the lungs, brain, and liver.

Current management focuses on symptom control through invasive procedures like cauterization and embolization, or the off-label use of systemic drugs like bevacizumab and thalidomide, which can carry significant side effects. Atavistik aims to change this with ATV-1601, an oral, allosteric inhibitor that selectively targets AKT1.

Hyperactivation of the AKT1 signaling pathway is a known driver of the abnormal endothelial growth that characterizes HHT. Previous attempts to develop pan-AKT inhibitors have been hampered by toxicities, most notably hyperglycemia, driven by the inhibition of the related AKT2 isoform. ATV-1601 was designed specifically to avoid this pitfall. Its selectivity was validated in a prior Phase 1 study in oncology patients, where it demonstrated a favorable safety profile without the side effects that limit pan-AKT inhibitors. This existing human safety data significantly de-risks its development and provides a strong foundation for its pivot into HHT, where it has the potential to be a disease-modifying, all-comers therapy.

Precision Targeting in Rare Blood Cancers

Atavistik is applying the same principle of precision to its second lead program for myeloproliferative neoplasms (MPNs), a group of rare, chronic blood cancers. A specific genetic mutation, JAK2 V617F, is the primary driver in the vast majority of patients with polycythemia vera and a significant portion of those with essential thrombocythemia and myelofibrosis.

Existing treatments, such as the pan-JAK inhibitor ruxolitinib, provide symptom relief but do not discriminate between the mutant JAK2 protein and its healthy, wild-type counterpart. This non-selective inhibition limits their ability to eliminate the underlying driver of the disease—the mutant allele burden—and can disrupt normal blood cell production, leading to adverse events and treatment discontinuation.

Atavistik’s program aims to develop a truly mutant-selective inhibitor that targets only the JAK2 V617F protein. Such a therapy could potentially reduce the population of cancerous cells while preserving the function of healthy bone marrow. This would represent a major leap forward, shifting the treatment goal from symptom management to deep, durable, and disease-modifying responses that could substantially improve long-term outcomes for patients.

With $160 million in fresh capital, a scientifically validated platform, and two highly promising programs targeting diseases with dire unmet needs, Atavistik Bio is strongly positioned to translate the elegant science of allosteric inhibition into transformative medicines for patients.